These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 16168113

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
    Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D, Amadori D.
    Int J Cancer; 1999 Jan 29; 80(3):413-6. PubMed ID: 9935183
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S.
    Cancer Res; 1999 Feb 01; 59(3):734-41. PubMed ID: 9973225
    [Abstract] [Full Text] [Related]

  • 5. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
    Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG.
    Cancer Res; 2002 May 01; 62(9):2644-9. PubMed ID: 11980662
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53.
    Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitão C, Steer CJ, Rodrigues CM.
    Biochim Biophys Acta; 2007 Jan 01; 1772(1):40-7. PubMed ID: 17056233
    [Abstract] [Full Text] [Related]

  • 7. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O, Arce F, Gätjens-Boniche O, Díaz C.
    Biomed Pharmacother; 2007 Jul 01; 61(6):347-55. PubMed ID: 17399942
    [Abstract] [Full Text] [Related]

  • 8. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Kurebayashi J, Nukatsuka M, Sonoo H, Uchida J, Kiniwa M.
    Cancer Chemother Pharmacol; 2010 Jan 01; 65(2):219-25. PubMed ID: 19455332
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells.
    Han Q, Chen R, Wang F, Chen S, Sun X, Guan X, Yang Y, Peng B, Pan X, Li J, Yi W, Li P, Zhang H, Feng D, Chen A, Li X, Li S, Yin Z.
    PLoS One; 2018 Jan 01; 13(4):e0192888. PubMed ID: 29617363
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low-dose doxorubicin with carotenoids selectively alters redox status and upregulates oxidative stress-mediated apoptosis in breast cancer cells.
    Vijay K, Sowmya PR, Arathi BP, Shilpa S, Shwetha HJ, Raju M, Baskaran V, Lakshminarayana R.
    Food Chem Toxicol; 2018 Aug 01; 118():675-690. PubMed ID: 29920287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
    Inoue Y, Tanaka K, Hiro J, Yoshiyama S, Toiyama Y, Eguchi T, Miki C, Kusunoki M.
    Int J Oncol; 2006 Feb 01; 28(2):479-86. PubMed ID: 16391804
    [Abstract] [Full Text] [Related]

  • 18. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR, Fryar-Tita EB, Zhou Y, Green S, Southerland WM, Bowen D.
    Anticancer Res; 2007 Feb 01; 27(6B):3791-9. PubMed ID: 18225534
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.